Imagine replacing thick, clunky metal wires in the brain with ultra-thin graphene dots. These dots act like high-definition microphones that can hear a single brain cell instead of a loud crowd. By using AI to translate these signals, doctors can pinpoint exactly where a brain disorder is happening and fix it with precision.
Current brain implants use large metal leads that are too invasive and lack the resolution to target specific neural cells, leaving 25-35% of neurological patients without effective treatment options.
A platform of graphene-based neural implants including a high-resolution acute cortical interface for mapping and a chronic implantable platform for therapeutic modulation.
If you are a device manufacturer dealing with the low resolution and high invasiveness of metal leads — this project developed graphene-based neural implants that read single neural cells. This allows for the detection of therapy-specific biomarkers to improve personalized treatment.
If you are a BCI firm dealing with the difficulty of translating thought to speech in impaired patients — this project developed a high-resolution acute cortical interface. This tool enables precise brain mapping to accelerate the development of communication interfaces.
If you are a clinic dealing with the 25-35% of patients who do not respond to drugs — this project developed a chronic implantable platform for network decoding. This provides a safe alternative for treating Parkinson's and Epilepsy through adaptive responses.
Based on available project data, specific pricing or cost-per-unit information is not provided.
The project has developed new industrial processes at INBRAIN to fabricate the novel design, indicating a move toward scalable manufacturing.
Based on available project data, specific licensing terms are not mentioned, but the technology is being developed by INBRAIN Neuroelectronics SL.
The project period runs from 2023-05-01 to 2025-04-30, with the cortical interface already being tested in a first-in-human setting.
The implants are designed to be powered by artificial intelligence to detect biomarkers and trigger adaptive responses for personalized therapy.
The project is led by a single Spanish SME, INBRAIN Neuroelectronics SL, which holds 100% of the industry ratio. This lean structure suggests a highly focused commercial drive, as the company manages both the R&D and the industrial fabrication processes internally.
Contact INBRAIN Neuroelectronics SL in Spain regarding their graphene-based neural interface platform.
Contact SciTransfer to explore partnership opportunities with INBRAIN for BCI integration.
